Washington: The growing popularity of the weight loss drug Wegovy or Ozempic has raised concerns about potential side effects. However, a recent study has dismissed these concerns.
A new study has refuted public fears regarding popular weight loss medications. Researchers found that the use of these drugs does not increase the risk of depression or suicide.
Analysis of clinical trial data revealed that semaglutide medications did not increase the risks of depression, suicidal thoughts, or suicidal behaviors in individuals without pre-existing mental health issues.
The new study reviewed data from over 3,500 people in four major clinical trials for semaglutide. These trials were funded by Novo Nordisk, the company behind Ozempic and Wegovy.